Study to evaluate the safety of MAQ-001 as monotherapy and combination therapy in patients with advanced cancers
Phase 1
Recruiting
- Conditions
- Advanced cancer histologies for which immune checkpoint blockade is an approved treatment option, such as: Metastatic melanoma, Lung cancer, Renal Cell Carcinoma (RCC), Hodgkin’s lymphoma, Microsatellite Instability (MSI)-high colon cancer, Hepatocellular Carcinoma (HCC), and Gastric cancer.Therapeutic area: Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]
- Registration Number
- CTIS2023-507774-41-00
- Lead Sponsor
- MabQuest S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method